Zacks Research Brokers Increase Earnings Estimates for Prestige Consumer Healthcare Inc. (NYSE:PBH)

Prestige Consumer Healthcare Inc. (NYSE:PBH) – Stock analysts at Zacks Research upped their FY2024 earnings per share estimates for Prestige Consumer Healthcare in a research note issued to investors on Monday, April 22nd. Zacks Research analyst R. Department now forecasts that the company will post earnings of $4.33 per share for the year, up from their previous forecast of $4.32. The consensus estimate for Prestige Consumer Healthcare’s current full-year earnings is $4.33 per share. Zacks Research also issued estimates for Prestige Consumer Healthcare’s Q4 2024 earnings at $1.14 EPS, Q4 2026 earnings at $1.20 EPS and FY2026 earnings at $4.75 EPS.

Prestige Consumer Healthcare (NYSE:PBH) last released its earnings results on Thursday, February 8th. The company reported $1.06 earnings per share for the quarter, topping analysts’ consensus estimates of $1.04 by $0.02. Prestige Consumer Healthcare had a negative net margin of 7.11% and a positive return on equity of 14.09%. The firm had revenue of $282.74 million for the quarter, compared to the consensus estimate of $280.25 million. During the same period in the prior year, the firm earned $1.04 EPS. The company’s revenue was up 2.6% compared to the same quarter last year.

Several other analysts also recently weighed in on PBH. TheStreet upgraded Prestige Consumer Healthcare from a “c+” rating to a “b-” rating in a research note on Monday, February 12th. StockNews.com raised Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research note on Saturday, February 10th. One investment analyst has rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $110.00.

Prestige Consumer Healthcare Trading Up 0.2 %

Shares of NYSE PBH opened at $69.80 on Tuesday. The company has a quick ratio of 1.92, a current ratio of 3.09 and a debt-to-equity ratio of 0.75. The company has a 50 day simple moving average of $70.73 and a two-hundred day simple moving average of $63.94. Prestige Consumer Healthcare has a fifty-two week low of $55.96 and a fifty-two week high of $75.31.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. GAMMA Investing LLC purchased a new position in shares of Prestige Consumer Healthcare during the fourth quarter valued at approximately $25,000. Pacer Advisors Inc. raised its stake in Prestige Consumer Healthcare by 85.7% during the 4th quarter. Pacer Advisors Inc. now owns 442 shares of the company’s stock valued at $27,000 after buying an additional 204 shares during the last quarter. Provence Wealth Management Group purchased a new stake in Prestige Consumer Healthcare during the 3rd quarter valued at $26,000. Principal Securities Inc. bought a new position in shares of Prestige Consumer Healthcare during the 4th quarter valued at $29,000. Finally, ORG Partners LLC purchased a new position in shares of Prestige Consumer Healthcare in the 4th quarter worth $36,000. Institutional investors own 99.95% of the company’s stock.

Insider Activity

In related news, SVP Mary Beth Fritz sold 5,336 shares of the business’s stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $69.00, for a total value of $368,184.00. Following the completion of the transaction, the senior vice president now directly owns 15,934 shares in the company, valued at approximately $1,099,446. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 1.60% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.